Indivior PLC (NASDAQ:INDV – Get Free Report)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $10.88, but opened at $12.64. Indivior shares last traded at $12.93, with a volume of 182,069 shares trading hands.
Analysts Set New Price Targets
Several research firms recently commented on INDV. Piper Sandler began coverage on Indivior in a report on Tuesday. They issued an “overweight” rating and a $22.00 target price on the stock. Craig Hallum decreased their price objective on shares of Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, July 10th.
View Our Latest Stock Analysis on INDV
Indivior Stock Up 16.3 %
Indivior (NASDAQ:INDV – Get Free Report) last announced its earnings results on Thursday, April 25th. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.01). The business had revenue of $284.00 million for the quarter, compared to analyst estimates of $300.00 million. Indivior had a return on equity of 842.72% and a net margin of 0.44%. As a group, sell-side analysts forecast that Indivior PLC will post 1.8 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in INDV. Chilton Investment Co. Inc. purchased a new position in Indivior in the fourth quarter valued at about $263,000. ADAR1 Capital Management LLC purchased a new position in Indivior in the fourth quarter valued at about $368,000. Cannon Global Investment Management LLC acquired a new stake in Indivior during the first quarter worth approximately $563,000. Campbell & CO Investment Adviser LLC boosted its position in Indivior by 2.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after acquiring an additional 1,037 shares during the last quarter. Finally, Forsta AP Fonden acquired a new stake in Indivior during the first quarter worth approximately $641,000. 60.33% of the stock is owned by hedge funds and other institutional investors.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Conviction Firms For Chipotle Stock’s 25% Share Price Increase
- How to Use the MarketBeat Stock Screener
- Beauty Retailer Stock Brings Early Christmas for Value Investors
- Investing in the High PE Growth Stocks
- Ford Stock EPS Disappoints, Shares Plummet After-Hours
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.